Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nicotine gum · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Nicotine gum | EXPERIMENTAL | Nicotine gum |
| Placebo gum | PLACEBO_COMPARATOR | Placebo gum |
| Nicotine inhaler | ACTIVE_COMPARATOR | Nicotine inhaler |
| Placebo inhaler | PLACEBO_COMPARATOR | Placebo inhaler |
| Name | Type | Description |
|---|---|---|
| Nicotine gum | DRUG | 8-12 pieces per day, maximum 24 daily |
| Placebo gum | DRUG | 8-12 pieces per day, maximum 24 daily |
| Nicotine inhaler | DRUG | 6-12 cartridges per day, maximum 12 daily |
| Placebo inhaler | DRUG | 6-12 cartridges per day, maximum 12 daily |
Inclusion Criteria: * Age above 18 * Smoking \>/= 15 cigarettes/day * Having smoked for 3 years or more * CO \>/= 10ppm at inclusion * Want to reduce smoking * Prepared to adhere to the protocol * Willing to provide signed informed consent * Having made at least one serious attempt to quit smoking ...
Nicotine gum is used for smoking cessation. It is a small molecule therapy being developed by Johnson & Johnson (NYSE: JNJ) as a nicotine replacement treatment to help people stop smoking. The drug is currently in Phase 3 clinical development and is being studied in patients who want to quit smoking.
Nicotine gum works by delivering nicotine to the body to replace the nicotine obtained from cigarettes, reducing withdrawal symptoms and cravings associated with smoking cessation. It is a nicotine replacement therapy that helps smokers gradually reduce their nicotine dependence. The gum is administered orally and releases nicotine as it is chewed.
Nicotine gum is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. Johnson & Johnson is conducting clinical trials to evaluate the safety and efficacy of nicotine gum for smoking cessation.
Nicotine gum is in Phase 3 clinical development for smoking cessation. It is an investigational drug that has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the results will help determine whether the drug can be submitted for regulatory approval.
Nicotine gum has one completed Phase 3 clinical trial, identified as NCT00840242, titled "Smoking Reduction or Cessation With Nicotine Replacement Therapy." The trial enrolled 314 participants in Czechia and was a randomized, double-blind, placebo-controlled study. The trial included adults aged 18 years and older of all sexes.
Nicotine gum is a form of nicotine replacement therapy (NRT). NRT is a class of medications that deliver nicotine to the body without the harmful chemicals found in tobacco smoke. Nicotine gum specifically delivers nicotine through chewing, helping to reduce withdrawal symptoms and cravings during smoking cessation.